Close

Ratings by BMO Capital (Etzer Darout)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
4/9/2024 BioNTech BNTX Maintain Outperform
(N/A)
 
 
  Details
4/5/2024 Y-mAbs Therapeutics YMAB Maintain Outperform
(N/A)
 
 
  Details
3/21/2024 BioNTech BNTX Maintain Outperform
(N/A)
 
 
  Details
3/15/2024 Terns Pharmaceuticals TERN Maintain Outperform
(N/A)
 
 
  Details
3/12/2024 CytomX Therapeutics CTMX Maintain Market Perform
(N/A)
 
 
  Details
3/8/2024 MacroGenics MGNX Maintain Outperform
(N/A)
 
 
  Details
3/4/2024 Y-mAbs Therapeutics YMAB Maintain Outperform
(N/A)
 
 
  Details
2/29/2024 Merus N.V. MRUS Maintain Outperform
(N/A)
 
 
  Details
2/28/2024 Arvinas Inc. ARVN Maintain Outperform
(N/A)
 
 
  Details
2/28/2024 Nuvalent NUVL Maintain Outperform
(N/A)
 
 
  Details
2/28/2024 Xencor, Inc. XNCR Maintain Outperform
(N/A)
 
 
  Details
2/27/2024 Fate Therapeutics FATE Maintain Market Perform
(N/A)
 
 
  Details
2/23/2024 C4 Therapeutics CCCC Maintain Outperform
(N/A)
 
 
  Details
2/23/2024 Novartis NVS New Coverage Market Perform
(N/A)
102.80
(93.52)
-9.03% Details
2/23/2024 Genmab A/S GMAB Upgrade Outperform
(Market Perform)
29.11
(29.26)
0.52% Details
2/23/2024 BioNTech BNTX New Coverage Outperform
(N/A)
93.57
(86.48)
-7.58% Details
2/12/2024 AstraZeneca AZN Maintain Outperform
(N/A)
 
 
  Details
12/1/2023 Immunogen Inc. IMGN Downgrade Market Perform
(Outperform)
16.06
(31.25)
94.58% Details
11/10/2023 Acrivon Therapeutics Inc ACRV Maintain Outperform
(N/A)
 
 
  Details
11/9/2023 Fate Therapeutics FATE Maintain Market Perform
(N/A)
 
 
  Details
11/8/2023 CytomX Therapeutics CTMX Maintain Market Perform
(N/A)
 
 
  Details
11/8/2023 Xencor, Inc. XNCR Maintain Outperform
(N/A)
 
 
  Details
11/2/2023 C4 Therapeutics CCCC Maintain Outperform
(N/A)
 
 
  Details
10/18/2023 Nuvalent NUVL Maintain Outperform
(N/A)
 
 
  Details
10/5/2023 Nuvalent NUVL Maintain Outperform
(N/A)
 
 
  Details
8/4/2023 Xencor, Inc. XNCR Maintain Outperform
(N/A)
 
 
  Details
8/1/2023 AstraZeneca AZN Maintain Outperform
(N/A)
 
 
  Details
8/1/2023 Immunogen Inc. IMGN Maintain Outperform
(N/A)
 
 
  Details
5/10/2023 CytomX Therapeutics CTMX Maintain Market Perform
(N/A)
 
 
  Details
5/10/2023 Xencor, Inc. XNCR Maintain Outperform
(N/A)
 
 
  Details
5/10/2023 Y-mAbs Therapeutics YMAB Maintain Outperform
(N/A)
 
 
  Details
5/8/2023 Terns Pharmaceuticals TERN New Coverage Outperform
(N/A)
12.46
(5.14)
-58.75% Details
5/8/2023 Acrivon Therapeutics Inc ACRV New Coverage Outperform
(N/A)
12.53
(9.99)
-20.27% Details
5/3/2023 Immunogen Inc. IMGN Maintain Outperform
(N/A)
 
 
  Details
4/18/2023 Merus N.V. MRUS Maintain Outperform
(N/A)
 
 
  Details
3/16/2023 Merus N.V. MRUS Maintain Outperform
(N/A)
 
 
  Details
3/14/2023 Seagen SGEN Downgrade Market Perform
(Outperform)
172.61
(228.74)
32.52% Details
2/23/2023 Arvinas Inc. ARVN Maintain Outperform
(N/A)
 
 
  Details
2/16/2023 Seagen SGEN Maintain Outperform
(N/A)
 
 
  Details
2/10/2023 AstraZeneca AZN Maintain Outperform
(N/A)
 
 
  Details
1/6/2023 CytomX Therapeutics CTMX Maintain Market Perform
(N/A)
 
 
  Details
1/6/2023 Fate Therapeutics FATE Downgrade Market Perform
(Outperform)
11.12
(5.77)
-48.11% Details
1/5/2023 AstraZeneca AZN New Coverage Outperform
(N/A)
69.50
(68.93)
-0.82% Details
1/5/2023 Foghorn Therapeutics FHTX New Coverage Outperform
(N/A)
6.53
(7.42)
13.63% Details
12/20/2022 Seagen SGEN Maintain Outperform
(N/A)
 
 
  Details
12/20/2022 Genmab A/S GMAB Maintain Market Perform
(N/A)
 
 
  Details
12/20/2022 Xencor, Inc. XNCR Maintain Outperform
(N/A)
 
 
  Details
12/20/2022 Merus N.V. MRUS Maintain Outperform
(N/A)
 
 
  Details
12/20/2022 Fate Therapeutics FATE Maintain Outperform
(N/A)
 
 
  Details
12/20/2022 Arvinas Inc. ARVN Maintain Outperform
(N/A)
 
 
  Details
11/16/2022 Immunogen Inc. IMGN Maintain Outperform
(N/A)
 
 
  Details
11/14/2022 CytomX Therapeutics CTMX Downgrade Market Perform
(Outperform)
1.29
(2.15)
66.67% Details
11/14/2022 MacroGenics MGNX Upgrade Outperform
(Market Perform)
6.73
(17.54)
160.62% Details
11/11/2022 Nuvalent NUVL Maintain Outperform
(N/A)
 
 
  Details
11/11/2022 Genmab A/S GMAB Maintain Market Perform
(N/A)
 
 
  Details
11/8/2022 Arvinas Inc. ARVN Maintain Outperform
(N/A)
 
 
  Details
11/4/2022 MacroGenics MGNX Maintain Market Perform
(N/A)
 
 
  Details
10/31/2022 Y-mAbs Therapeutics YMAB Maintain Outperform
(N/A)
 
 
  Details
10/28/2022 Nuvalent NUVL Maintain Market Perform
(N/A)
 
 
  Details
10/11/2022 Seagen SGEN Upgrade Outperform
(Market Perform)
130.95
(228.74)
74.68% Details
9/12/2022 Seagen SGEN Maintain Market Perform
(N/A)
 
 
  Details
7/11/2022 Fate Therapeutics FATE Upgrade Outperform
(Market Perform)
30.01
(5.77)
-80.77% Details
7/11/2022 MacroGenics MGNX Downgrade Market Perform
(Outperform)
3.50
(17.54)
401.14% Details
7/7/2022 CytomX Therapeutics CTMX Maintain Outperform
(N/A)
 
 
  Details
6/24/2022 Seagen SGEN New Coverage Market Perform
(N/A)
169.66
(130.95)
-22.82% Details
6/24/2022 Genmab A/S GMAB New Coverage Market Perform
(N/A)
30.43
(29.26)
-3.84% Details
6/24/2022 CytomX Therapeutics CTMX New Coverage Outperform
(N/A)
1.80
(2.15)
19.44% Details
6/24/2022 Nuvalent NUVL New Coverage Outperform
(N/A)
12.01
(65.51)
445.46% Details
6/24/2022 Y-mAbs Therapeutics YMAB New Coverage Outperform
(N/A)
13.88
(14.37)
3.53% Details
5/6/2022 Xencor, Inc. XNCR Maintain Outperform
(N/A)
 
 
  Details
4/11/2022 C4 Therapeutics CCCC Maintain Outperform
(N/A)
 
 
  Details
3/1/2022 Arvinas Inc. ARVN Maintain Outperform
(N/A)
 
 
  Details
2/11/2022 Arvinas Inc. ARVN New Coverage Outperform
(N/A)
74.68
(36.29)
-51.41% Details
2/11/2022 C4 Therapeutics CCCC New Coverage Outperform
(N/A)
24.51
(7.41)
-69.77% Details
2/11/2022 Fate Therapeutics FATE New Coverage Market Perform
(N/A)
40.95
(30.01)
-26.72% Details
2/11/2022 MacroGenics MGNX New Coverage Outperform
(N/A)
11.76
(3.50)
-70.24% Details
2/11/2022 Merus N.V. MRUS New Coverage Outperform
(N/A)
26.14
(41.85)
60.1% Details
2/11/2022 Xencor, Inc. XNCR New Coverage Outperform
(N/A)
35.32
(20.48)
-42.02% Details
2/11/2022 Immunogen Inc. IMGN New Coverage Outperform
(N/A)
6.00
(31.25)
420.83% Details